Baxalta (BXLT) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up 1% as Saudi Arabian refinery attack reignites supply concerns
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- S&P Global explores potential separation of Capital IQ business
- Wall Street ends higher on revived AI momentum
- Nebius Group shares jump after France data center funding
- GE Vernova Inc. (GEV) Tops Q3 EPS by 81c, Beats on Revenue; Offers FY26 Revenue Guidance
- Seagate Technology (STX) Tops Q1 EPS by 29c, Offers Guidance
Baxalta Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key Milestones
February 16, 2016 6:40 AM ESTResults reflect successful transition to a standalone company with compelling commercial, regulatory, clinical, operational and financial execution Broad and differentiated portfolio of leading hematology and immunology therapies driving sustainable growth and value Differentiated oncology portfolio augmented by pipeline progress and new, strategic immuno-oncology collaboration Significant advances toward delivering 20 new product launches by 2020 with key milestone achievements and FDA approvals of ADYNOVATE and VONVENDI
BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader... More



